Final Programme CINP 2014 - page 91

91
Faculty Disclosures
Albert, Paul:
Disclosure: None
Altar, Tony:
Disclosure: Genetic testing and funding
for data collection and analysis personnel were pro-
vided by AssureRx Health, Inc. Dr. Altar is em-
ployed by AssureRx Health, Inc.
Amara, Susan G:
Disclosure: None
Andersen, Peter:
Disclosure: None
Aston-Jones, Gary:
Disclosure: None
Belzung, Catherine:
Disclosure: None
Benedetti, Francesco:
Disclosure: None
Binder, Elisabeth:
Disclosure: None
Blier, Pierre:
Disclosure: Dr Blier received grants
and/or honoraria for giving lectures and/or partici-
pating in advisory boards for Astra Zeneca, Bristol
Myers Squibb, Eli Lilly, Forest, Janssen, Lundbeck,
Merck, Pfizer, Pierre Fabre Medicaments, Servier,
Sunovion, Takeda, and Valeant.
Booij, Linda:
Disclosure: None
Bousman, Chad:
Disclosure: None
Bunney, William:
Disclosure: None
Bussey, Tim:
Disclosure: None
Cahill, Catherine:
Disclosure: None
Chaki, Shigeyuki:
Disclosure: None
Chandler, Jennifer:
Disclosure: None
Churchill, Grant:
Disclosure: Certain authors hold a
patent on the use of ebselen for treating bipolar dis-
order.
Citrome, Leslie:
Disclosure: In the past 12 months,
L. Citrome, was a consultant for, has received hono-
raria from, or has engaged in collaborative research
supported by the following: Alexza, Alkermes, As-
traZeneca, Bristol-Myers Squibb, Eli Lilly, Envivo,
Forest, Genentech, Janssen, Lundbeck, Merck,
Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt
Benckiser, Reviva, Shire, Sunovion, and Takeda.
Collingridge, Graham:
Disclosure: None
Comai, Stefano:
Disclosure: None
Conn, P. Jeffrey:
Disclosure: Dr. Conn receives re-
search funding from Astrazeneca and Bristol Myers
Squibb and is an inventor on multiple patents pro-
tecting allosteric modulators of mGlu receptors and
muscarinic acetylcholine receptors.
Corlett, Philip R. :
Disclosure: I have no financial
conflicts of interest.
Cosford, Nicholas:
Disclosure: None
Coyle, Joseph:
Disclosure: JT Coyle, MD has con-
sulted with AbbVie and EnVivo within the last
2 years and holds a patent on the clinical use of
D-serine that is owned by Massachusetts General
Hospital. D. Balu, M. Puhl, M. Benneyworth and S.
Tagaki report no conflicts of interest. This research
was supported by grants from the N.I.H.
Cryan, John:
Disclosure: The authors are supported
in part by Science Foundation Ireland in the form of a
centre grant (Alimentary Pharmabiotic Centre Grant
Number SFI/12/RC/2273); by the Health Research
Board of Ireland (Grant Numbers HRA_POR/2011/23
and HRA_POR/2012/32) and received funding from
the European Community’s Seventh Framework Pro-
gramme Grant MyNewGut under Grant Agreement
No. FP7/2007-2013. The Centre has conducted stud-
ies in collaboration with several companies including
GSK, Pfizer, Cremo, Suntory, Wyeth and Mead John-
son. The authors have spoken at meetings sponsored
by food and pharmaceutical companies.
De Koninck, Yves:
Disclosure: None
Dean, Brian:
Disclosure: None
Deisseroth, Karl:
Disclosure: None
Duffy, Anne:
Disclosure: None
Duman, Ronald:
Disclosure: Dr. Duman is a consul-
tant and/or receives research funds from Taisho,
Sunovion, Lundbeck, Forest, Johnson & Johnson,
Naurex, and Lilly.
Everall, Ian:
Disclosure: None
Feero, Gregory W.:
Disclosure: None
Floresco, Stan:
Disclosure: None
Foster, Jane:
Disclosure: None
Franke, Barbara:
Disclosure: None
Frazer, Alan:
Disclosure: Previously, Dr. Frazer has
received financial support both as a consultant and
in the form of a grant from Cyberonics, Inc., the
manufacturer of the VNS stimulation device.
Gobbi, Gabriella:
Disclosure: Dr Gobbi has been a
speaker for Eli Lilly and Merck, and has received
grant/honoraria from GlaxoSmithKline, Merck, and
AstraZeneca in the past.In the past 12 months,
speaker: AstraZeneca
Grace, Anthony:
Disclosure: Johnson & Johnson,
Lundbeck, Pfizer, GSK, Puretech Ventures, Merck,
Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche,
Asubio, Abbott
Greenshaw, Andrew J. :
Disclosure: There is no fi-
nancial conflict of interest for any of the proposed
speakers.
Groß-Lesch, Silke:
Disclosure: I declare that I re-
ceived speakers fees from Medice Company.
Gründer, Gerhard:
Disclosure: Gerhard Gründer
has been on advisory boards, acted as consultant,
has been on the speaker's bureau and received
grant support from the following companies: Che-
plapharm, Eli Lilly, Gedeon Richter, Lundbeck,
Roche, Servier, Takeda.
Hampson, David R. :
Disclosure: This work was
supported by the Fragile X Research Foundation of
Canada, Lundbeck Research Inc., and the Canadian
Institutes of Health Research. The author has no fi-
nancial conflict of interest.
Hashimoto, Ryota:
Disclosure: There is no financial
conflict of interest.
Hasler, Gregor:
Disclosure: None
1...,81,82,83,84,85,86,87,88,89,90 92,93,94,95,96,97,98,99,100,101,...120
Powered by FlippingBook